İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi

SELDA SAYIN KUTLU (Pamukkale Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Denizli, Türkiye)
Klimik Dergisi
4 3
Yıl: 2016 Cilt: 29 Sayı: 3 Sayfa Aralığı: 100 - 106 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi

Öz:
İnsan immün yetmezlik virusu (HIV), esas olarak cinsel ilişkiyle, kanla temasla ve perinatal yolla bulaşmaktadır. HIV bulaşmasını azaltmak için infekte kişilerin erken tanı ve tedavisi, güvenli cinsel ilişki, sünnet ve ortak injektör paylaşımının önlenmesinin yanı sıra temas öncesi ve sonrası antiretroviral profilaksi uygulamalarının önemi büyüktür. Bu yazıda HIV'e karşı temas sonrası ve temas öncesi profilaksi gözden geçirilmiştir.
Anahtar Kelime:

Konular: Mikrobiyoloji Enfeksiyon Hastalıkları

Prophylaxis Against Human Immunodeficiency Virus

Öz:
HIV is transmitted mainly by sexual contact, exposure to blood, and perinatally. To reduce HIV transmission, pre-exposure and post-exposure antiretroviral prophylaxis are of great importance other than early diagnosis and treatment of HIV-infected people, safe sexual contact, male circumcision, prevention of common syringe use. In this review, post- and pre-exposure prophylaxis against HIV are evaluated.
Anahtar Kelime:

Konular: Mikrobiyoloji Enfeksiyon Hastalıkları
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • Del Rio C, Curran JW. Epidemiology and prevention of acquired immunodeficiency syndrome and human immunodeficiency vi- rus infection. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Di- seases. 8th ed. Philadelphia: Elsevier Saunders, 2015: 1483-502.
  • Bell DM. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997; 102(5B): 9-15. [CrossRef]
  • Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommen- dations for postexposure prophylaxis. Infect Control Hosp Epi- demiol. 2013; 34(9): 875-92. [CrossRef]
  • Gilman CS. Postexposure HIV Prophylaxis in Physicians and Me- dical Personnel [İnternet]. New York, NY: Medscape [erişim 5 Ha- ziran 2016]. emedicine.medscape.com/article/1991375-overview.
  • Ippolito G, Puro V, De Carli G. The risk of occupational human im- munodeficiency virus infection in health care workers. Italian Mul- ticenter Study. The Italian Study Group on Occupational Risk of HIV infection. Arch Intern Med. 1993; 153(12): 1451-8. [CrossRef]
  • Sultan B, Benn P, Waters L. Current perspectives in HIV post- exposure prophylaxis. HIV AIDS (Auckl). 2014; 6: 147-58.
  • Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implica- tions for HIV prevention. Int J Epidemiol. 2010; 39(4): 1048-63. [CrossRef]
  • Pinto LA, Landay AL, Berzofsky JA, Kessler HA, Shearer GM. Im- mune response to human immunodeficiency virus (HIV) in he- althcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997; 102(5B): 21-4. [CrossRef]
  • Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infecti- on and route of viral dissemination after an intravaginal inocula- tion of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996; 183(1): 215-25. [CrossRef]
  • Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. RV254/ SEARCH 010 Study Group. J Infect Dis. 2012; 206(2): 275-82. [CrossRef]
  • HIV Prophylaxis Following Occupational Exposure (What's New - October 2014 Update) [İnternet]. New York, NY: New York Sta- te Department of Health AIDS Institute [erişim 5 Haziran 2016]. http://www.hivguidelines.org/wp-content/uploads/2016/03/HIV- Prophylaxis-Following-Occupational-Exposure_3-28-16.pdf.
  • HIV Prophylaxis Following Non-Occupational Exposure [İnter- net]. New York, NY: New York State Department of Health AIDS Institute [erişim 5 Haziran 2016]. http://www.hivguidelines.org/ wp-content/uploads/2016/03/nPEP_for-PDF_11-29-14.pdf.
  • Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needles- tick Surveillance Group. N Engl J Med. 1997; 337(21): 1485-90. [CrossRef]
  • Mast ST, Woolwine JD, Gerberding JL. Efficacy of gloves in re- ducing blood volumes transferred during simulated needlestick injury. J Infect Dis. 1993; 168(6): 1589-92. [CrossRef]
  • Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999; 340(21): 1614-22. [CrossRef]
  • Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Or- ganization Guidelines on Postexposure Prophylaxis for HIV: Re- commendations for a Public Health Approach. Clin Infect Dis. 2015; 60(Suppl. 3): S161-4. [CrossRef]
  • HIV Prophylaxis for Victims of Sexual Assault [İnternet]. New York, NY: New York State Department of Health AIDS Institu- te [erişim 5 Haziran 2016]. http://www.hivguidelines.org/wp- content/uploads/2014/10/hiv-prophylaxis-for-victims-of-sexual- assault.pdf.
  • Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Sci- ence. 1995; 270(5239): 1197-99. [CrossRef]
  • Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for pre- vention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998; 72(5): 4265-73.
  • Shih CC, Kaneshima H, Rabin L, et al. Postexposure prophyla- xis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis. 1991; 163(3): 625-7. [CrossRef]
  • Kaplan JE, Dominguez K, Jobarteh K, Spira TJ. Postexposure prophylaxis against human immunodeficiency virus (HIV): new guidelines from the WHO: a perspective. Clin Infect Dis. 2015; 60(Suppl. 39: S196-9.
  • Guidance for the Use of Pre-Exposure Prophylaxis (PrEP) to Pre- vent HIV Transmission (What's New - October 2015) [İnternet]. New York, NY: New York State Department of Health AIDS Ins- titute [erişim 5 Haziran 2016]. http://www.hivguidelines.org/wp- content/uploads/2016/02/PrEP-Guidance_10-14-15.pdf.
  • Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtrici- tabine to prevent HIV infection. J Antimicrob Chemother. 2011; 66(2): 240-50. [CrossRef]
  • Anderson PL. Pharmacology considerations for HIV prevention. Presentation at 13th International Workshop on Clinical Pharma- cology of HIV Therapy (16-18 April 2012, Barcelona) [İnternet]. Utrecht: Virology Education [erişim 5 Haziran 2016]. http://re- gist2.virology-education.com/2012/13hivpk/docs/16_Anderson. pdf.
  • Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5): 399-410. [CrossRef]
  • Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double- blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883): 2083-90. [CrossRef]
  • Grant RM, Lama JR, Anderson PL, et al. Preexposure chemop- rophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27): 2587-99. [CrossRef]
  • Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5): 423-34. [CrossRef]
  • FDA Approves First Drug For Reducing the Risk of Sexually Ac- quired HIV Infection [İnternet]. Silver Spring, MD: U.S. Food and Drug Administration [erişim 5 Haziran 2016]. http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210. htm.
  • Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016; 30(12): 1973-83. [CrossRef]
  • Guideline on When to Start Antiretroviral Therapy and on Pre- Exposure Prophylaxis for HIV (September 2015) [İnternet]. Ge- neva: World Health Organization [erişim 5 Haziran 2016]. http:// apps.who.int/iris/bitstream/10665/186275/1/9789241509565_ eng.pdf.
  • Guidance on Oral Pre-Exposure Prophylaxis (Prep) For Serodis- cordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects (July 2012) [İnternet]. Gene- va: World Health Organization [erişim 5 Haziran 2016]. http:// apps.who.int/iris/bitstream/10665/75188/1/9789241503884_eng. pdf?ua=1.
  • Consolidated Guidelines on HIV Prevention, Diagnosis, Treat- ment and Care for Key Populations (July 2014) [İnternet]. Ge- neva: World Health Organization [erişim 5 Haziran 2016]. http:// apps.who.int/iris/bitstream/10665/128048/1/9789241507431_ eng.pdf?ua=1&ua=1.
  • Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the Internatio- nal Antiviral Society-USA Panel. JAMA. 2014; 312(4): 390-409. [CrossRef]
  • Preexposure Prophylaxis for HIV Prevention in the United States - 2014. A Clinical Practice Guideline [İnternet]. Atlanta, GA: Cen- ters for Disease Control and Prevention [erişim 5 Haziran 2016]. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf.
APA SAYIN KUTLU S (2016). İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. , 100 - 106.
Chicago SAYIN KUTLU SELDA İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. (2016): 100 - 106.
MLA SAYIN KUTLU SELDA İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. , 2016, ss.100 - 106.
AMA SAYIN KUTLU S İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. . 2016; 100 - 106.
Vancouver SAYIN KUTLU S İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. . 2016; 100 - 106.
IEEE SAYIN KUTLU S "İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi." , ss.100 - 106, 2016.
ISNAD SAYIN KUTLU, SELDA. "İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi". (2016), 100-106.
APA SAYIN KUTLU S (2016). İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. Klimik Dergisi, 29(3), 100 - 106.
Chicago SAYIN KUTLU SELDA İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. Klimik Dergisi 29, no.3 (2016): 100 - 106.
MLA SAYIN KUTLU SELDA İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. Klimik Dergisi, vol.29, no.3, 2016, ss.100 - 106.
AMA SAYIN KUTLU S İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. Klimik Dergisi. 2016; 29(3): 100 - 106.
Vancouver SAYIN KUTLU S İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi. Klimik Dergisi. 2016; 29(3): 100 - 106.
IEEE SAYIN KUTLU S "İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi." Klimik Dergisi, 29, ss.100 - 106, 2016.
ISNAD SAYIN KUTLU, SELDA. "İnsan İmmün Yetmezlik Virusuna Karşı Profilaksi". Klimik Dergisi 29/3 (2016), 100-106.
Sayfa Oluşturulma Tarihi
23-04-2024 1:19

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları